Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Terbutaline Turbuhaler · 2 trials · 1 indication
FEV1 (Forced Expiratory Volume in 1 second) AUC 0-4 hours after drug inhalation
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI ⇒salbutamol pMDI 200 μg +placebo Turbuhaler® |
| 2 | EXPERIMENTAL | salbutamol pMDI 200 μg +placebo Turbuhaler® ⇒Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI |
| Name | Type | Description |
|---|---|---|
| Terbutaline Turbuhaler® | DRUG | 0.4 mg, inhalation, single dose |
| Salbutamol pMDI | DRUG | 200 μg, inhalation, single dose |
| pMDI placebo pMDI | OTHER | Placebo pMDI 2 inhalations |
| Placebo Turbuhaler® | OTHER | Placebo Turbuhaler 1 inhalation |
| Budesonide/Formoterol Turbuhaler | DRUG | - |
| Budesonide Turbuhaler (Pulmicort) | DRUG | - |
| Terbutaline Turbuhaler | DRUG | - |
Inclusion Criteria: * On ICS for at least 3 months from Visit 2 and with a prescribed constant dose during the 4 weeks prior to Visit 2 * Forced Expiratory Volume in 1 Second (FEV1) of at least 50 % of predicted normal value pre-bronchodilator * Reversible airway obstruction according to reversibil...
Terbutaline Turbuhaler is a small molecule drug developed by AstraZeneca PLC for the treatment of asthma. It is administered via a dry powder inhaler device. The drug is currently in Phase 3 clinical development, meaning it is investigational and has not yet been approved for use.
Terbutaline Turbuhaler is developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. The drug is being studied for the treatment of asthma and is currently in Phase 3 clinical trials.
Terbutaline Turbuhaler is in Phase 3 clinical development for the treatment of asthma. It is an investigational drug, meaning it has not yet received regulatory approval. Two Phase 3 trials have been completed, with a total of 124 participants enrolled across multiple countries.
Terbutaline Turbuhaler has been studied in two completed Phase 3 trials. NCT00244608 compared asthma control with Symbicort Turbuhaler versus Symbicort Turbuhaler plus Pulmicort Turbuhaler plus Terbutaline Turbuhaler, enrolling 100 adults. NCT01096017 investigated the relative efficacy of Terbutaline Turbuhaler versus salbutamol pMDI in 24 participants.
Terbutaline Turbuhaler is not the same as Symbicort Turbuhaler. Symbicort is a combination product containing budesonide and formoterol, while Terbutaline Turbuhaler contains only terbutaline. In clinical trial NCT00244608, the two were studied together, with Symbicort used alone or in combination with Pulmicort and Terbutaline.